Kite Submits Supplemental Biologics License Application to U.S. FDA for Earlier Use of Yescarta in Large B-Cell Lymphoma

Kite has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for Yescarta to expand its current indication to include the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) in the second-line setting. The sBLA filing is based on data from Kite’s landmark ZUMA-7 study. If approved, Yescarta would become the first CAR T-cell therapy for adults with LBCL who relapse after or are refractory to first-line therapy.

Press release